STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma

被引:39
作者
Bisikirska, B. C. [1 ]
Adam, S. J. [2 ,3 ]
Alvarez, M. J. [1 ]
Rajbhandari, P. [1 ]
Cox, R. [1 ,4 ]
Lefebvre, C. [1 ]
Wang, K. [5 ,6 ]
Rieckhof, G. E. [1 ]
Felsher, D. W. [2 ,3 ]
Califano, A. [1 ,5 ,7 ]
机构
[1] Columbia Univ, Joint Ctr Syst Biol, New York, NY USA
[2] Stanford Univ, Div Oncol, Dept Med, Stanford, CA 94305 USA
[3] Stanford Univ, Div Oncol, Dept Pathol, Stanford, CA 94305 USA
[4] Riverdale Country Sch, Bronx, NY USA
[5] Columbia Univ, Dept Biomed Informat, New York, NY USA
[6] Pfizer Inc, San Diego, CA USA
[7] Columbia Univ, Dept Pathol & Genet & Dev, New York, NY USA
关键词
STK38; MYC post-translational modifications; protein turnover; transcriptional activity; protein-protein interaction; NDR PROTEIN-KINASE; C-MYC; TRANSCRIPTION FACTOR; TUMOR-REGRESSION; ACTIVATION; COMPLEX; BINDING; DNA; PHOSPHORYLATION; IDENTIFICATION;
D O I
10.1038/onc.2012.543
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The MYC protooncogene is associated with the pathogenesis of most human neoplasia. Conversely, its experimental inactivation elicits oncogene addiction. Besides constituting a formidable therapeutic target, MYC also has an essential function in normal physiology, thus creating the need for context-specific targeting strategies. The analysis of post-translational MYC activity modulation yields novel targets for MYC inactivation. Specifically, following regulatory network analysis in human B-cells, we identify a novel role of the STK38 kinase as a regulator of MYC activity and a candidate target for abrogating tumorigenesis in MYC-addicted lymphoma. We found that STK38 regulates MYC protein stability and turnover in a kinase activity-dependent manner. STK38 kinase inactivation abrogates apoptosis following B-cell receptor activation, whereas its silencing significantly decreases MYC levels and increases apoptosis. Moreover, STK38 knockdown suppresses growth of MYC-addicted tumors in vivo, thus providing a novel viable target for treating these malignancies.
引用
收藏
页码:5283 / 5291
页数:9
相关论文
共 52 条
[1]  
Adeyinka A, 2002, CLIN CANCER RES, V8, P3788
[2]   The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc [J].
Arnold, Hugh K. ;
Zhang, Xiaoli ;
Daniel, Colin J. ;
Tibbitts, Deanne ;
Escamilla-Powers, Julie ;
Farrell, Amy ;
Tokarz, Sara ;
Morgan, Charlie ;
Sears, Rosalie C. .
EMBO JOURNAL, 2009, 28 (05) :500-512
[3]   Gene Ontology: tool for the unification of biology [J].
Ashburner, M ;
Ball, CA ;
Blake, JA ;
Botstein, D ;
Butler, H ;
Cherry, JM ;
Davis, AP ;
Dolinski, K ;
Dwight, SS ;
Eppig, JT ;
Harris, MA ;
Hill, DP ;
Issel-Tarver, L ;
Kasarskis, A ;
Lewis, S ;
Matese, JC ;
Richardson, JE ;
Ringwald, M ;
Rubin, GM ;
Sherlock, G .
NATURE GENETICS, 2000, 25 (01) :25-29
[4]   Intrinsically disordered proteins: regulation and disease [J].
Babu, M. Madan ;
van der Lee, Robin ;
de Groot, Natalia Sanchez ;
Gsponer, Joerg .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 2011, 21 (03) :432-440
[5]  
Bansal M, 2012, METHODS MOL BIOL, V786, P131, DOI 10.1007/978-1-61779-292-2_8
[6]   Reverse engineering of regulatory networks in human B cells [J].
Basso, K ;
Margolin, AA ;
Stolovitzky, G ;
Klein, U ;
Dalla-Favera, R ;
Califano, A .
NATURE GENETICS, 2005, 37 (04) :382-390
[7]   Structure of the Ca2+/S100B/NDR kinase peptide complex:: Insights into S100 target specificity and activation of the kinase [J].
Bhattacharya, S ;
Large, E ;
Heizmann, CW ;
Hemmings, B ;
Chazin, WJ .
BIOCHEMISTRY, 2003, 42 (49) :14416-14426
[8]   SEQUENCE-SPECIFIC DNA-BINDING BY THE C-MYC PROTEIN [J].
BLACKWELL, TK ;
KRETZNER, L ;
BLACKWOOD, EM ;
EISENMAN, RN ;
WEINTRAUB, H .
SCIENCE, 1990, 250 (4984) :1149-1151
[9]  
BONNEFOYBERARD N, 1994, BLOOD, V83, P1051
[10]   Control of cell proliferation by Myc [J].
Bouchard, C ;
Staller, P ;
Eilers, M .
TRENDS IN CELL BIOLOGY, 1998, 8 (05) :202-206